| Name | EMT inhibitor-1 |
| Description | EMT inhibitor-1 is a compound that inhibits Hippo and Wnt signaling pathways, as well as TGF- macrophages (TGF-), exhibiting antitumor activity. |
| In vitro | EMT inhibitor-1 (C19) inhibiting cancer cell migration, proliferation, and resistance to doxorubicin in vitro.EMT inhibitor-1 (C19) (0-10μM; 24 hours) is an inhibitor of of Hippo, TGF-β, and Wnt signaling pathways with antitumor activities[1]. |
| In vivo | EMT inhibitor-1 (C19) (intraperitoneal injection; 5-20 mg/kg) demonstrates significant antitumor activity in a mouse tumor model. Mechanistically, it induces GSK3-β–mediated degradation of the Hippo transducer TAZ through activation of the Hippo kinases Mst/Lats and the tumor suppressor kinase AMPK, which are upstream of the degradation complex. C19 is dissolved in the vehicle solution (100 μL of DMEM containing 5% dimethyl sulfoxide) [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (783.18 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (10.34 mM), Sonication is recommended.
|
| Keywords | βcatenin | Wnt/β-catenin | Wnt/betacatenin | Wnt/b-catenin | Wnt | EMT inhibitor-1 | EMT inhibitor1 | EMT inhibitor 1 | beta-catenin | betacatenin | bcatenin |
| Inhibitors Related | Chlorquinaldol | Urea | Melamine | SB-431542 | Hydrochlorothiazide | Neohesperidin | Ethyl linoleate | Pirfenidone | A 83-01 | Cetrimonium bromide | Galunisertib | Methyl Vanillate |
| Related Compound Libraries | Anti-Lung Cancer Compound Library | Reprogramming Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Anti-Alzheimer's Disease Compound Library | Anti-Cancer Metabolism Compound Library | Hematonosis Compound Library | Inhibitor Library | Neuroprotective Compound Library | Bioactive Compounds Library Max | Wnt/Hedgehog/Notch Compound Library | Anti-Cancer Active Compound Library |